Rosetta Genomics reports that it has won the first patent covering miRNA composition of matter relating to a human or viral miRNA gene.
"We believe the issuance of this patent, and future such patents, will allow exclusive partnership opportunities and increases the value proposition across our broad product development pipeline for microRNA-based diagnostics and therapeutics," says Amir Avniel, president and CEO of Rosetta.